Jack Kaye Sells 1,993 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 1,993 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the sale, the director directly owned 25,996 shares of the company’s stock, valued at $703,451.76. This trade represents a 7.12% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jack Kaye also recently made the following trade(s):

• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The shares were sold at an average price of $30.01, for a total transaction of $79,376.45.

uniQure Price Performance

Shares of uniQure stock opened at $27.57 on Friday. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a fifty day moving average of $22.52 and a 200-day moving average of $21.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. Equities research analysts expect that uniQure N.V. will post -3.64 EPS for the current year.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares in the last quarter. Aberdeen Group plc raised its holdings in uniQure by 6.9% in the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares in the last quarter. Quinn Opportunity Partners LLC bought a new position in uniQure in the 3rd quarter worth $6,281,000. Farallon Capital Management LLC raised its holdings in uniQure by 3,935.7% in the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after purchasing an additional 551,000 shares in the last quarter. Finally, Boone Capital Management LLC bought a new position in uniQure in the 3rd quarter worth $8,599,000. 78.83% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on QURE shares. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $11.00 to $35.00 in a research note on Monday, March 9th. Chardan Capital upped their price target on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Barclays lowered their price target on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. HC Wainwright lowered their price target on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.